| Open Document File Size: 54,77 KBShare Result on Facebook
City Nutley / / Company Hoffmann-La Roche Inc. / / Country United States / / IndustryTerm healthcare personnel / / MedicalCondition fatal infections / severe hypersensitivity / vomiting / wound infections / opportunistic infections / lymphoproliferative disorders / hypersensitivity / diarrhea / severe infections / GI disorders / constipation / Cellulitis / nausea / anaphylaxis / / MedicalTreatment immunosuppressive therapy / antibody therapy / immunosuppression / organ transplant / renal transplants / / Organization Roche Pharmaceuticals Service Center / ZENAPAX administration / / Person Lars E. Birgerson / / / Position physician responsible / Vice President / US Medical Affairs / / Product ZENAPAX / cyclosporine / / ProvinceOrState New Jersey / / Technology transplantation / /
SocialTag |
September 2009 IMPORTANT DRUG INFORMATION Dear Healthcare Professional: Roche would like to advise you that production of ZENAPAX® (daclizumab) Sterile Concentrate for Injection has been discontinued for the United Stat